

# Clinical trials of angiogenesis inhibitors for lung cancer in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 bevacizumab

Trial	Treatments	Patients	Trials design and methods
<b>bevacizumab vs</b>			
<a href="#">65279;Reck , 2010</a> n=NA	GP+bev versus GP	-	
<a href="#">Sandler , 2006</a> n=NA	PCp +bev versus PCp	-	
<a href="#">Johnson , 2004</a> n=NA	PCp +bev versus PCp	-	
<a href="#">Nishio , 2009</a> n=NA	PCp +bev versus PCp	-	
<a href="#">Herbst , 2007</a> n=NA	D/M +bev versus D/M	-	
<a href="#">Herbst , 2011</a> n=NA	erl+bev versus erl	-	

## References

### 65279;Reck, 2010:

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leigh N, Mezger J, Archer V, Moore N, Manegold C Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol* 2009;27:1227-34 [[19188680](#)] [10.1200/JCO.2007.14.5466](https://doi.org/10.1200/JCO.2007.14.5466)

### Sandler, 2006:

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 2006;355:2542-50 [[17167137](#)] [10.1056/NEJMoa061884](https://doi.org/10.1056/NEJMoa061884)

### Johnson, 2004:

Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. *J Clin Oncol* 2004;22:2184-91 [[15169807](#)] [10.1200/JCO.2004.11.022](https://doi.org/10.1200/JCO.2004.11.022)

### Nishio, 2009:

Nishio M, Horai T, Kunitoh H, Ichinose Y, Nishiwaki Y, et al. Randomized, open-label, multicenter phase II study of bevacizumab in combination with carboplatin and paclitaxel in chemotherapy-naïve Japanese patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): JO19907. available from: <http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8036> Accessed 2012 May 26

**Herbst, 2007:**

Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. *J Clin Oncol* 2007;25:4743-50 [[17909199](#)] [10.1200/JCO.2007.12.3026](#)

**Herbst, 2011:**

Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. *Lancet* 2011;377:1846-54 [[21621716](#)] [10.1016/S0140-6736\(11\)60545-X](#)

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.